CCT128930

News alerts, weekly reports and conference planners

Company:

Otsuka

Drug class:

AKT inhibitor, p70S6K inhibitor

Related drugs:

‹

›

AKT2 expression	B Acute Lymphoblastic Leukemia	AKT2 expression	B Acute Lymphoblastic Leukemia	CCT128930 Sensitive: D – Preclinical CCT128930 Sensitive : D	CCT128930 Sensitive: D – Preclinical CCT128930 Sensitive : D
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	CCT128930 Sensitive: D – Preclinical CCT128930 Sensitive : D	CCT128930 Sensitive: D – Preclinical CCT128930 Sensitive : D

Associations
(2)